By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Paper in @jclinicalinvest (bit.ly/497z6jo) by @HopkinsMedicine @JHUMed_ID finds patient living w/ #HIV has dramatic drop in ...
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...
Clinical Trials Arena on MSN
Gilead’s HIV ART combo deemed non-inferior in second phase III trial
Gilead has already had success with the single-pill combination therapy in the ARTISTRY-1 trial.
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
By Sriparna Roy Dec 15 (Reuters) - Gilead Sciences said on Monday its experimental HIV treatment was found to be ...
Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback